We are pleased to share that EA Pharma Co., Ltd. has entered into an exclusive worldwide license agreement with Ensho Therapeutics, Inc. This agreement allows Ensho Therapeutics to develop, manufacture, and commercialize EA1080, a novel treatment for inflammatory bowel disease (IBD), outside Japan and certain Asian regions.? ? Ensho Therapeutics, established to further develop EA1080, brings together a team with extensive experience in global IBD treatment development. Through this collaboration, EA Pharma and Ensho Therapeutics aim to improve the quality of life for 5 million IBD patients worldwide.? ? Under the terms of the agreement, Ensho Therapeutics has already prepared a clinical development strategy,?and aims to commence Phase 2 clinical development in the first half of 2025.? ? We believe this partnership will have major impact on the immunology and inflammatory disease areas,?and contribute to healthier life for humanity globally.? ? For more details, see the press releases below:?? Ensho Therapeutics:??https://lnkd.in/gBYMm5uG? EA Pharma (Japanese only):?https://lnkd.in/gAyZTjRa? ? #WeAreAjinomotoGroup #Innovation #WellBeing #Collaboration #Research? ? EA Pharma: was established in April 2016 by integration of gastrointestinal business unit of Eisai Group and gastrointestinal business unit of the Ajinomoto Group, and its currently as a subsidiary of Eisai Group.?
关于我们
Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The company’s initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for IBD, a mechanism already validated by a commercially available antibody. Ensho’s assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program in UC with NSHO-101, the lead asset in the company’s pipeline.
- 网站
-
https://www.enshorx.com
Ensho Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 类型
- 私人持股
- 创立
- 2024
Ensho Therapeutics员工
动态
-
We are extremely excited to embark on our journey to develop breakthrough oral therapies for patients with inflammatory diseases. With the acquisition of a portfolio of novel, oral, selective α4β7 integrin inhibitors from EA Pharma, a subsidiary of Eisai, led by Phase 2-ready NSHO-101 (also known as EA1080), we are well-positioned to advance our clinical efforts in treating #IBD. Discover more about Ensho Therapeutics here:?https://lnkd.in/gZf_WH6p
-